ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Interest Income
Income earned on cash, deposits, and investments held by the company.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $2.79M rose 17.0% year over year, ahead of the -10.2% change in trailing-twelve-month interest income. Sequentially, it fell 14.9% from the prior quarter.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +17.0% holds above the trailing-twelve-month pace of -10.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 11.23M USD
- Year-over-year change
- -18.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.23M | -18.8% |
| FY2024 | 2024-12-31 | 13.82M | +162.9% |
| FY2023 | 2023-12-31 | 5.26M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Interest Income vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 interest income of $11.63M is the 8th highest of the 11 companies compared; the peer median is $20.46M.
- Its year-over-year change of -10.2% is the 5th highest of 11, against a peer median of -17.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $63.69M | -16.1% | +27.9% | 2.6% | |
| LTM Mar 2026 | $43.41M | -18.5% | +128.0% | 19.3% | |
| LTM Jun 2025 | $37.21M | +3.6% | +73.4% | 6.2% | |
| LTM Jun 2026 | $27.93M | -21.5% | +31.4% | 6.2% | |
| LTM Jun 2026 | $21.03M | -8.1% | +42.2% | 12.4% | |
| LTM Sep 2026 | $19.88M | +8.5% | +50.2% | — | |
| LTM Mar 2026 | $11.81M | -31.7% | +52.0% | — | |
| LTM Mar 2026 | $11.63M | -10.2% | — | — | |
| LTM Mar 2026 | $4.49M | +109.8% | +26.0% | — | |
| LTM Mar 2026 | $3.98M | -18.0% | +71.2% | 1.8% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding AVBP) | $20.46M | -17.0% | +50.2% | 6.2% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.